MAPK3 and neoplasm: It has been observed that, when iCCA cells are exposed to gemcitabine and cisplatin, the combined pharmacological inhibition of ERK1/2 with U0126 increases the sensitivity of tumor cells to chemotherapy-induced death, indicating that the ERK1/2 pathway is involved in resistance mechanisms [146].